Droxidopa / Pyridostigmine in Orthostatic Hypotension
Droxidopa / Pyridostigmine in Orthostatic Hypotension
The hypothesis is that pyridostigmine will improve the safety factor of ganglionic neural
 transmission, while Droxidopa will replete the postganglionic neuron of norepinephrine (NE).
 This combination should result in enhanced orthostatic release of NE. The investigators have
 already demonstrated that pyridostigmine does not raise supine blood pressure.
1. The presence of orthostatic hypotension (fall in systolic BP greater than or equal to
 30 mm Hg) is required for this study;

 2. Autonomic testing and clinical evaluation demonstrates OH to be of neurogenic
 etiology.